Cardiovascular diseases are the leading cause of morbidity and mortality and contribute most to healthcare costs in the U.S. Age is the strongest cardiovascular disease risk factor, with >90% of all deaths from cardiovascular disease occurring in adults >50 years old. The age-associated increased risk of cardiovascular disease is due, in large part, to the development of arterial dysfunction, including endothelial dysfunction and stiffening of the large elastic arteries. Therefore, novel, effective interventions that improve arterial function will have a large public health impact by decreasing the risk of cardiovascular diseases.
The short-chain fatty acid acetate is endogenously produced by the gut microbiome from fermentation of dietary soluble fiber. High-fiber diets reduce risk of cardiovascular diseases, but unfortunately, a low percentage of Americans meet guidelines for adequate dietary fiber intake and, despite nationwide efforts to improve this, trends in fiber intake have not improved over the last 20+ years. Thus, directly supplementing acetate may be a more practical and feasible intervention for effectively improving arterial function in older adults and reducing the risk of cardiovascular diseases.
The investigators will conduct a study to determine the efficacy of 12 weeks of oral supplementation with acetate for improving arterial function in late middle-aged and older (50+ years) adults. They will also assess the safety and tolerability of acetate supplementation in these adults and perform innovative mechanistic analyses to determine how acetate supplementation improves arterial function. The investigators hypothesize that oral acetate supplementation will improve arterial function by decreasing oxidative stress and increasing nitric oxide bioavailability, and also hypothesize that acetate supplementation will be safe and promote high rates of adherence.

开始日期2022-09-29

申办/合作机构

University of Colorado Denver

100 项与醋酸钙相关的临床结果

登录后查看更多信息

100 项与醋酸钙相关的转化医学

登录后查看更多信息

100 项与醋酸钙相关的专利（医药）

登录后查看更多信息

419

项与醋酸钙相关的文献（医药）

2024-02-12·Scientific reports

Long-term liming changes pasture mineral profile.

Article

作者: Guangdi D Li ; Mark K Conyers ; Gordon Refshauge ; Forough Ataollahi ; Richard C Hayes

There is limited information on changes of pasture mineral concentrations over the long-term in response to liming. A long-term field experiment was conducted to assess the influence of lime application on (a) changes in pasture mineral composition over time; and (b) key pasture mineral concentrations and ratios important to animal health. Perennial and annual pastures with or without lime application were sampled annually over 12 years and analysed for macro- and micro-minerals. Mineral ratios and indices were calculated to assess the potential impact on animal health. Liming increased the concentrations of calcium, sodium and silicon, but decreased the concentrations of micro-nutrients including copper, zinc and manganese. The same trend was found in both annual and perennial pastures although there were some fluctuations between years. Liming increased the calcium:phosphorus ratio and the dietary cation-anion difference but reduced the tetany index on both annual and perennial pastures. These findings suggest a potential benefit to improve animal health outcomes for some disorders on the limed pastures. However, the reduced concentrations of some trace elements following liming potentially decreases antioxidant capacity and requires further research.

2023-12-30·Materials (Basel, Switzerland)

The Evaluation of the Effectiveness of Biomineralization Technology in Improving the Strength of Damaged Fiber-Reinforced LWAC.

Article

作者: How-Ji Chen ; Tsung-Kai Chen ; Chao-Wei Tang ; Han-Wen Chang

Concrete cracks and local damage can affect the bond performance between concrete and steel bars, thereby reducing the durability of reinforced concrete structures. Compared with general concrete crack repair methods, biomineralization repair not only has effective bonding capabilities but is also particularly environmentally friendly. Therefore, this study aimed to apply biomineralization technology to repair damaged fiber-reinforced lightweight aggregate concrete (LWAC). Two groups of LWAC specimens were prepared. The experimental group used lightweight aggregates (LWAs) containing bacterial spores and nutrient sources, while the control group used LWAs without bacterial spores and nutrient sources. These specimens were first subjected to compression tests and pull-out tests, respectively, and thus were damaged. After the damaged specimen healed itself in different ways for 28 days, secondary compression and pull-out tests were conducted. The self-healing method of the control group involved placing the specimens in an incubator. The experimental group was divided into experimental group I and experimental group II according to the self-healing method. The self-healing method of experimental group I was the same as that of the control group. The self-healing method of experimental group II involved soaking the specimen in a mixed solution of urea and calcium acetate for two days, and then taking it out and placing it in an incubator for two days, with a cycle of four days. The test results show that in terms of the relative bond strength ratio, the experimental group II increased by 17.9% compared with the control group. Moreover, the precipitate formed at the cracks in the sample was confirmed to be calcium carbonate with the EDS and XRD analysis results, which improved the compressive strength and bond strength after self-healing. This indicates that the biomineralization self-healing method used in experimental group II is more effective.

2023-12-18·Chemosphere

Formulation of PG-FA-L composite modifier for repairing expansive soil based on the statistical mixed design method.

Article

作者: Fusheng Zha ; ChuanQing Hu ; Bo Kang ; Lin Qin ; Jie Li ; ChengFu Chu

The generation of large amounts of solid waste has led to exploration of solid waste-modified expansive soils; however, the effect of a single solid waste-modified expansive soil is not ideal. This study proposes a composite modification of expansive soils using a PG-FA-L system. Statistical analysis showed that the properties of the cured soil were significantly improved. PG and FA increased soil strength after a certain threshold, and L increased it at all stages. The presence of PG accelerated the volcanic ash reaction. Both PG and FA have a small effect on the swelling of the soil, whereas lime improves it significantly, but has a negative effect after a certain threshold. The 28-day unconfined compressive strength and deformation characteristics were used to derive the relevant regions for roadbed fill requirements and determine the optimum dosage.

项与醋酸钙相关的新闻（医药）

2024-04-07

·米内网

3月5个首仿、3个1类新药获批，4个品种获批新适应症，这家企业仿制申报最多

摘要abstract2024年3月7个1类新药、5个改良型新药申请上市；167个品种按新分类仿制申请申报，其中33个品种暂无国内仿制获批，石家庄四药申报品种数最多；32个存量品种有企业申报一致性评价，其中2个品种为首次申报。3款1类新药获批上市，4个品种获批新适应症；15个品种首家过评，其中5个为首仿。创新药品种申报情况2024年3月，97个创新药品种（药品注册分类为“1”的品种）获CDE承办。7个品种申请上市：己二酸他雷替尼胶囊(葆元生物医药(杭州))、盐酸来罗西利片(玉溪嘉和生物)、盐酸去甲乌药碱注射液(珠海润都制药)、注射用Datopotamab Deruxtecan(第一三共)、注射用苏维西塔单抗(江苏先声生物)、通络健脑片(广州悦康生物制药)、紫花温肺止嗽颗粒(广州悦康生物制药)。2024年3月创新药上市申请承办情况2024年3月创新药临床申请承办情况改良型新药品种申报情况2024年3月，19个改良型新药品种获CDE承办，5个品种申请上市，呋喹替尼胶囊(和记黄埔医药(上海))、古塞奇尤单抗注射液(强生)、聚乙二醇干扰素α-2b注射液(厦门特宝生物)、赛沃替尼片(和记黄埔医药(上海))为新适应症上市申请。2024年3月改良型新药上市申请承办情况2024年3月改良型新药临床申请承办情况新分类仿制药品种申报情况2024年3月，167个品种仿制申请获CDE承办，33个品种目前暂无国内仿制药获批。石家庄四药共有10个品种获CDE承办：比拉斯汀片、二羟丙茶碱注射液、复方醋酸钠林格注射液、富马酸福莫特罗吸入溶液、精氨酸培哚普利片、氯化钙注射液、吗啉硝唑氯化钠注射液、葡萄糖酸钙注射液、盐酸尼卡地平氯化钠注射液、盐酸左沙丁胺醇雾化吸入溶液。2024年3月新分类仿制药品种申报情况存量品种一致性评价申报情况2024年3月，32个品种的一致性评价补充申请获CDE承办。法罗培南钠片和复合磷酸氢钾注射液为首次申报。2024年3月存量品种一致性评价申报情况获批情况2024年3月有3款1类新药获批上市：秦威颗粒(成都华西天然药物)、妥拉美替尼胶囊(上海科州药物研发)、泽沃基奥仑赛注射液(恺兴生命科技(上海))。4个品种获批新适应症：佩索利单抗注射液(皮下注射)(勃林格殷格翰)、舒格利单抗注射液(辉瑞)、阿布昔替尼片(辉瑞)、阿那白滞素注射液(苏庇医药)。103个品种按新分类仿制申请获批，44个品种按存量品种一致性评价补充申请过评。15个品种首家过评，其中ω-3甘油三酯(2%)中/长链脂肪乳/氨基酸(16)/葡萄糖(16%)注射液(四川科伦药业)、醋酸钙口服溶液(山东朗诺制药)、盐酸阿那格雷胶囊(黑龙江天宏药业)、依折麦布辛伐他汀片(北京福元医药)、注射用塞替派(江苏恒瑞医药)等5个品种为国内首仿。2024年3月主要注册类型品种获批情况数据来源：米内网中国申报进度数据库（MED）、CDE、NMPA；相关统计字段按药品名称统计，时间截至2024年3月31日；获批品种按NMPA发布时间统计；药物作用靶点以及适应症整理自公开资料。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

一致性评价上市批准

2024-04-03

·药融圈

140品种密集过评！4大首仿重磅获批，恒瑞医药、科伦药业等药企强势登榜……

▲5月30-31日第八届广州生物医药创新者峰会扫码立即报名注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。据药融云数据库统计，3月，CDE共承办277条新注册分类仿制药申报受理号和55条一致性评价补充申请，涉及药企超260家。在申报品种数量上，浙江赛默制药持续发力，本月申报了15个品种，占居榜首。紧随其后的是石家庄四药，提交了12个品种的申报，展现了不俗的实力。在过评方面，3月共有140个品种（238品规）通过/视同通过一致性评价，涉及155家企业，恒瑞医药、科伦药业等多家药企强势登榜。浙江赛默制药持续发力，占居榜首3月，CDE共承办277条新注册分类仿制药申报受理号和55条一致性评价补充申请，涉及药企超260家。本月申报品种最集中的领域是心血管系统用药，其次是神经系统用药。截图来源：药融云中国药品审评数据库-全局分析环比上月企业申报情况，本月浙江赛默制药持续发力，申报了15个品种，占居榜首。紧随其后的是石家庄四药，提交了12个品种的申报，展现了不俗的实力。浙江赛默制药3月申报情况数据来源：药融云中国药品审评数据库从受理品种来看，二羟丙茶碱注射液、米诺地尔搽剂、注射用尼可地尔3个品种的相关申报企业数最多。截图来源：药融云中国药品审评数据库-全局分析 4大首仿重磅获批，恒瑞医药、科伦药业等药企强势登榜3月共有140个品种（238品规）通过/视同通过一致性评价，涉及155家企业。本月华润双鹤、江苏万高药业、成都苑东生物制药、北京福元医药、四川科伦药业、恒瑞医药等20家药企强势登榜，均有2个品种过评。数据来源：药融云过评药品汇总数据库在过评品种中，普瑞巴林胶囊、注射用尼可地尔的过评企业数最多，达到5家。注射用头孢他啶、阿立哌唑口服溶液、玻璃酸钠滴眼液、盐酸多巴胺注射液、盐酸帕洛诺司琼注射液、地夸磷索钠滴眼液、氨溴特罗口服溶液、盐酸多巴酚丁胺注射液8个品种均有3家企业过评。首家过评品种方面，本月共有15个品种迎来首家过评，涉及华润双鹤、江苏恒瑞医药、四川科伦药业、北京福元医药等多家药企。其中盐酸阿那格雷胶囊、依折麦布辛伐他汀片、ω-3甘油三酯(2%)中长链脂肪乳/氨基酸(16)/葡萄糖(16%)注射液、醋酸钙口服溶液4个品种迎来首仿。3月首家过评品种（标红为首仿）数据来源：药融云过评药品汇总数据库版权声明：本文转自药融云，如不希望被转载的媒体或个人可与我们联系，我们将立即删除活动推荐 5月 • 第八届大湾区生物医药创新者峰会关键词：小分子，XDC，多肽及GLP-1热点话题，80+行业专家（点击下方图片查看详情）▼【关于药融圈】药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等多个领域，服务了百余家上市/独角兽/生物技术/制药企业。

一致性评价

2024-04-01

·赛柏蓝

钙制剂市场，品牌、企业排名公布（附5图）

编者按：本文来自米内网，作者张自然；赛柏蓝授权转载，编辑yuki01规模近年来，我国钙制剂市场规模不断扩大，新品牌不断涌现。中国三大终端六大市场钙制剂合计市场规模由2019年的114亿元增加到2022年的154亿元，三年增加了40亿元，增长了35%。其中，城市实体药店终端市场份额占比最高，2022年占据全国市场的55%，其次是公立医疗机构终端占38%，网上药店终端占7%。增速最快的是网上药店终端，由2019年的约3亿元增加到2022年的超11亿元，三年增长了3倍。2019-2022年中国三大终端六大市场钙制剂市场规模及分布来源：米内网格局数据库，张自然整理02药店城市实体药店终端是钙制剂最主要的市场，销售规模由2019年的约60亿元增加到2022年的超80亿元，三年增加约24亿元，增长了39%。品牌TOP20方面，钙制剂市场份额最大的品牌是碳酸钙D3片(Ⅱ)（北京朗迪制药），2023年上半年销售额在12亿元以上，占该终端钙制剂市场的28.9%。市场份额＞10%且＜20%的品牌有1个，为碳酸钙D3片（惠氏），占比11.9%；市场份额＞7%且＜10%的品牌有4个，分别为碳酸钙D3颗粒(Ⅱ)（北京朗迪制药，占9.5%）、碳酸钙维D3元素片(4)（惠氏，占8.7%）、碳酸钙D3咀嚼片(Ⅲ)（安士，占8.4%）、复方葡萄糖酸钙口服溶液（哈药三精，占7.6%）；市场份额＞2%且＜7%的品牌有3个，分别为碳酸钙D3咀嚼片(Ⅱ)（惠氏，占4%）、小儿碳酸钙D3颗粒（安士，占2.7%）、碳酸钙D3咀嚼片（山东威高药业，占2.5%）。在TOP20品牌中，进口/合资品牌有6个，占比30%，分别属于惠氏和安士制药。2023年上半年城市实体药店终端钙制剂品牌TOP20市场份额来源：米内网中国公立医疗机构药品终端竞争格局，张自然整理注：蓝色柱为进口/合资品牌企业TOP20方面，钙制剂市场份额最大的企业是北京朗迪制药，2023年上半年销售额近17亿元，占该终端钙制剂市场的38.4%。第二位是惠氏，占比24.5%；第三位是安士制药，占比12.1%；第四位是哈药三精制药，占比7.6%；第五位是山东威高药业，占比2.5%。在城市实体药店终端，钙制剂市场企业集中度较高，前三名合计占据其市场的3/4。TOP20企业中，外企/合资企业有2家，占比10%，分别为惠氏和安士制药。2023年上半年城市实体药店终端钙制剂企业TOP20市场份额来源：米内网中国公立医疗机构药品终端竞争格局，张自然整理注：蓝色柱为外企/合资企业03医疗机构公立医疗机构终端是钙制剂的第二大市场，销售规模由2019年约50亿元增加到2022年的近60亿元，三年增加了7亿元，增长了14%。其品牌和企业市场格局与城市实体药店终端均有所不同。品牌TOP20方面，钙制剂市场份额最大的品牌也是碳酸钙D3片(Ⅱ)（北京朗迪制药），2023年上半年销售额超过6亿元，占该终端钙制剂市场的20.5%。市场份额＞10%且＜20%的品牌有1个，为碳酸钙D3片（惠氏），占比18.2%；市场份额＞5%且＜10%的品牌有4个，分别为醋酸钙胶囊（昆明邦宇制药，占6.8%）、碳酸钙D3咀嚼片（山东威高药业，占6.2%）、碳酸钙D3片(Ⅱ)（北京朗迪制药，占6%）、维D2磷葡钙片（华润双鹤，占5.6%）；市场份额＞2%且＜5%的品牌有3个，分别为碳酸钙D3咀嚼片(Ⅲ)（安士制药，占4.6%）、碳酸钙D3片(Ⅰ)（海南金泰药业，占4%）、醋酸钙颗粒（昆明邦宇制药，占2.2%）。在公立医疗机构终端TOP20品牌中，进口/合资品牌共3个（涉及惠氏和安士制药），占比15%，远少于其在城市实体药店终端的品牌数量（6个）。2023年上半年公立医疗机构终端钙制剂品牌TOP20市场份额来源：米内网中国公立医疗机构药品终端竞争格局，张自然整理注：蓝色柱为进口/合资品牌企业TOP20方面，钙制剂市场份额最大的企业也是北京朗迪制药，2023年上半年销售额近8亿元，占该终端钙制剂市场的26.6%。第二位也是惠氏，占比18.9%；第三位是昆明邦宇制药，占比9%；山东威高药业和安士制药并列第四，各占6.2%；第五位是华润双鹤，占比5.6%；海南金泰药业和河北天成药业分别位居第6、7位，各占4%和3.3%。2023年上半年公立医疗机构终端钙制剂企业TOP20市场份额来源：米内网中国公立医疗机构药品终端竞争格局，张自然整理注：蓝色柱为外企/合资企业总体而言，我国钙制剂市场不断扩容，国产品牌占主导地位，北京朗迪制药的碳酸钙D3片(Ⅱ)雄踞榜首。惠氏和安士制药2家外企/合资企业表现不俗。END内容沟通：13810174402医药代表交流群扫描下方二维码加入银发经济市场机遇交流群扫描下方二维码加入左下角「关注账号」，右下角「在看」，防止失联

申请上市

100 项与醋酸钙相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00931	醋酸钙	V03AE07	DB00258

研发状态

适应症	最高研发状态	国家/地区	公司
终末期肾脏病	批准上市	美国更多	Fresenius Medical Care North America Holdings LP 更多
-	批准上市	中国更多	-
高磷血症	撤市	美国更多	Fresenius Medical Care North America Holdings LP 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00211978 (Pubmed \| BMC Nephrol)	临床3期	慢性肾病	110	Calcium acetate	(膚膚蓋夢廠鹽網鏇壓觸) = 網觸鹽網窪選醖淵鏇觸選觸鹽襯夢顧夢積膚鏇 (衊選顧蓋構積鑰繭觸鹹 )	积极	2011-02-16
				Placebo	(膚膚蓋夢廠鹽網鏇壓觸) = 鹽糧選簾積廠衊範選餘選觸鹽襯夢顧夢積膚鏇 (衊選顧蓋構積鑰繭觸鹹 )
NCT01135615 (Pubmed \| Am J Kidney Dis)	临床4期	慢性肾病	100	Sevelamer	築蓋餘鏇齋醖糧網艱膚(繭鏇顧襯憲獵衊顧築鑰) = 鹽製鹹糧艱鬱鏇鬱範憲繭蓋構鑰齋獵繭構糧襯 (願鹹糧憲觸餘廠艱遞醖 )	-	2012-02-01
				Calcium Acetate	築蓋餘鏇齋醖糧網艱膚(繭鏇顧襯憲獵衊顧築鑰) = 鹹憲選餘憲遞觸獵夢壓繭蓋構鑰齋獵繭構糧襯 (願鹹糧憲觸餘廠艱遞醖 )